CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
High Eudragit® Content Vaginal Film +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04391036
NCT04391036N/ACompleted

A Randomized Double-Blind Cross-Over Study of Self-Insertion of Two Formulations of a Placebo Vaginal Film

Katherine Bunge·interventional·Posted May 18, 2020·Updated Feb 22, 2022

In Brief

A clinical study evaluating High Eudragit® Content Vaginal Film and Low Eudragit® Content Vaginal Film for Safety and Acceptability. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is a double-blinded crossover study to evaluate whether Eudragit® content impacts the ability to self-insert placebo vaginal films. Thirty women will self-insert one high and and one low Eudragit® content film. The insertion order will be randomized in a 1:1 ratio. After inserting each film, participants will complete a survey reporting their perceptions and experience. The primary endpoint is successful insertion defined as all of the film inside the vagina upon visual assessment by a study clinician. Secondary outcomes include preference for the low level or high level Eudragit® formulation film with respect to insertion and participants' description of identified challenges.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMay 18, 2020
Enrollment StartJul 14, 2020
Primary CompletionOct 26, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.1 years ago

Interventions

High Eudragit® Content Vaginal Filmdevice

High (12.8%) Eudragit® Content Vaginal Film

Low Eudragit® Content Vaginal Filmdevice

Low (6.4%) Eudragit® Content Vaginal Film